S7 Ep11: Treating Together: Navigating Treatment Decisions in Relapsed NPM1-Mutant AML: Practical Insights for Clinical Care
Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options.
Dr Roboz emphasized the importance of comprehensive mutational reassessment at relapse, as co-mutation profiles can change from initial diagnosis. She distinguished between mutational profiling for treatment…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.